REFERENCES
- Cooper A. M., Magram J., Ferrante J., Orme I. M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J. Exp. Med. 1997; 186: 39–45
- Gubler U., Chua A. O., Schoenhaut D. S., Dwyer C. M., McComas W., Motyka R., Nabavi N., Wolitzky A. G., Quinn P. M., Familletti P. C., et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA. 1991; 88: 4143–4147
- Hayes M. P., Wang J., Norcross M. A. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995; 86: 646–650
- Hiramoto J. S., Tsung K., Bedolli M., Norton J. A., Hirose R. Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12. J. Surg. Res 2004; 116: 64–69
- Kobayashi M., Fitz L., Ryan M., Hewick R. M., Clark S. C., Chan S., Loudon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 1989; 170: 827–845
- Ma X., Chow J. M., Gri G., Carra G., Gerosa F., Wolf S. F., Dzialo R., Trinchieri G. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 1996; 183: 147–157
- Magram J., Connaughton S. E., Warrier R. R., Carvajal D. M., Wu C. Y., Ferrante J., Stewart C., Sarmiento U., Faherty D. A., Gately M. K. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996; 4: 471–481
- Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., Gately M.K., Louis J. A., Alber G. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 1996; 26: 1553–1559
- McGrath-Morrow S., Laube B., Tzou S. C., Cho C., Cleary J., Kimura H., Rose N. R., Caturegli P. IL-12 overexpression in mice as a model for Sjogren lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291: L837–846
- McInnes I. B., Liew F. Y. Cytokine networks–towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2005; 1: 31–39
- Muller U., Kohler G., Mossmann H., Schaub G. A., Alber G., Di Santo J. P., Brombacher F., Holscher C. IL-12-independent IFN-gamma production by T cells in experimental Chagas' disease is mediated by IL-18. J. Immunol. 2001; 167: 3346–3353
- Phenekos C., Vryonidou A., Gritzapis A. D., Baxevanis C. N., Goula M., Papamichail M. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation 2004; 11: 209–213
- Snijders A., Hilkens C. M., van der Pouw Kraan T. C., Engel M., Aarden L. A., Kapsenberg M. L. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J. Immunol. 1996; 156: 1207–1212
- Stern A. S., Podlaski F. J., Hulmes J. D., Pan Y. C., Quinn P. M., Wolitzky A. G., Familletti P.C., Stremlo D.L., Truitt T., Chizzonite R., et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA. 1990; 87: 6808–6812
- Tsung K., Norton J. A. Lessons from Coley's Toxin. Surg. Oncol. 2006; 15: 25–28
- Yoshikawa H., Sato K., Edahiro S., Furukawa Y., Maruta T., Iwasa K., Watanabe H., Takaoka S., Suzuki Y., Takamori M., Yamada M. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J. Neuroimmunol. 2006; 175: 169–175